CASE REPORT

Association of idiopathic hepatic sinusoidal dilatation with the immunological features of the antiphospholipid syndrome

D Saadoun, D Cazals-Hatem, M-H Denninger, L Boudaoud, B-N Pham, V Mallet, B Condat, J Brière, D Valla

Background: Isolated sinusoidal dilatation is an uncommon hepatic lesion and the cause is largely unknown.

Objective: To investigate whether prothrombotic disorders or perisinusoidal cell changes could be involved in pure idiopathic hepatic sinusoidal dilatation (HSD).

Methods: Evaluation for associated conditions, prothrombotic disorders, and studies of hepatic perisinusoidal cell activation in consecutive patients, seen between 1993 and 2002, with isolated sinusoidal dilatation unrelated to outflow block, sinusoidal infiltration, or hepatic granulomas.

Results: Among 11 patients, associated conditions were prothrombotic disorders (n = 5) and oral contraceptive use (n = 3). Prothrombotic disorders were polycythaemia vera (n = 1) and antiphospholipid antibodies combined with lupus anticoagulant (n = 4). No genetic thrombophilia factor was found. Of four patients with lupus anticoagulant, three had antinuclear factors and high serum levels of antiphospholipid antibodies at repeated testing. There was no evidence of intrahepatic or extrahepatic thrombosis in any of the patients. Sinusoidal dilatation was marked in six of 11 patients (54%), including two patients with antiphospholipid antibodies. Activated perisinusoidal cells were only found around markedly dilated sinusoids.

Conclusion: Idiopathic pure HSD is frequently associated with the immunological features of the antiphospholipid syndrome. Therefore, finding pure HSD in a liver biopsy specimen should prompt the search for antiphospholipid antibodies.

Hepatic sinusoidal dilatation (HSD) is characterised by widening of hepatic capillaries which may involve the entire lobule or predominate in the central, perportal, or medial area.1 Peliosis hepatis differs from sinusoidal dilatation by the formation of blood lakes without preferential location.2 HSD can be encountered in three different situations. Firstly, sinusoidal dilatation is commonly found in the vicinity of hepatic tumours or in patients with heart failure, hepatic venous outflow block, veno-occlusive disease, granulomatous disorders, infectious conditions, or infiltration of sinusoids by various types of benign or malignant cells.3–6 Secondly, sinusoidal dilatation is common in the clinicopathological entity non-cirrhotic intrahepatic portal hypertension which consists of various types of architectural alterations. These alterations include nodular regenerative hyperplasia, perisinusoidal fibrosis, hepatoporal sclerosis, or incomplete septal cirrhosis.7–11 These architectural alterations have been related to several causal factors, including xenobiotics (thorium salts, arsenicals, vinyl chloride, vitamin A, or azathioprine)12 and thrombophilia.11 All of these factors have been postulated to act by inducing portal or sinusoidal obstruction.11 Thirdly, exceptional sinusoidal dilatation is an isolated finding of unclear origin.2 It is then referred to as idiopathic, although a role for oral contraceptives has been debated.2 Irrespective of the three situations above, a role for activated perisinusoidal cells can be speculated because of their contractile properties which may explain sinusoidal stenoses and dilatation.11 12

The aims of this study were: (a) to assess whether the prothrombotic disorders that have been implicated in non-cirrhotic intrahepatic portal hypertension are also implicated in isolated HSD and (b) to investigate whether perisinusoidal cell changes could be involved in pure idiopathic HSD.

PATIENTS AND METHODS

Patients
All patients referred between 1993 and 2002 to the hepatology unit of Beaujon Hospital for unexplained hepatic test abnormalities and in whom liver biopsy showed pure idiopathic HSD at histological analysis were considered. Pure idiopathic HSD was defined as isolated HSD without fibrosis, inflammation, congestion, or architectural changes (see histological analyses below) diagnosed in patients without the following conditions: heart or blood disorders; granulomatous, malignant, inflammatory, or infectious diseases; or obstructed hepatic or portal veins. Search for these associated conditions was based on a complete medical history and physical examination, chest radiograph, blood cell counts, erythrocyte sedimentation rate and C reactive protein determination, complete ultrasound or computed tomography scan of the abdomen, and liver histological analysis. All patients underwent Doppler ultrasound for evaluation of hepatic thrombosis.

All cases were obtained from a pathological database. Between 1993 and 2002, 42 patients were found to have HSD on liver biopsy in the absence of the following conditions: heart disorders, malignant diseases, or obstructed hepatic veins. Eleven of 42 patients fulfilled the inclusion criteria of pure idiopathic HSD. After giving written informed consent, all patients were investigated for a prothrombotic state.

Investigations for prothrombotic disorders
All patients were routinely investigated for a prothrombotic state. Lupus anticoagulant was investigated as previously described.15 A commercial kit was used to assay antiphospholipid antibodies of IgG and IgM types (Biogenic, Montpellier, France). Antithrombin and protein C functional deficiencies, and total and/or free protein S antigenic
deficiencies were assessed using commercial kits (Diagnostica Stago, Asnières, France). Genetic analyses were performed according to previously reported methods for G1691A factor V and G202110A prothrombin. Plasma total homocysteine levels were measured using high performance liquid chromatography with fluorometric detection. Endogenous erythroid colonies and total red cells were assessed as previously reported in nine patients (patient Nos 1, 2, 3, 5, 6, 7, 8, 9, and 10) to exclude an occult myeloproliferative disorder. Patient Nos 4 and 11 refused bone marrow aspiration. Evaluation of the CD55-CD59 cluster was performed to rule out paroxysmal nocturnal haemoglobinuria.

**Histological analyses**

Liver biopsy slides were reviewed by the same pathologist. Pure sinusoidal dilatation was defined as sinusoidal spaces more than one hepatocyte plate in width without any other histological abnormality in haematoxylin-eosin stained slides. The degree of dilatation was graded as moderate when sinusoidal spaces were at most two plates wide, and marked beyond this width. Gordon Sweet and Masson stains were used to exclude cases with perisinusoidal fibrosis. Immunohistochemical staining was carried out to detect activated perisinusoidal cells, using the three step immunoperoxidase technique without pretreatment. We used the following primary antibodies: monoclonal anti-α-smooth muscle actin (α-SMA) (1A4, dilution 1/25; Dako, Glostrup, Denmark) and anti-CD34 (QBEND 10, dilution 1/50; Immunotech, Marseille, France). Using our procedure, no α-SMA positive perisinusoidal cells were detectable in normal adult liver (in revascularisation biopsy at transplantation). The presence of activated perisinusoidal cells was based on detection of α-SMA positive and CD34 negative cells in Disse spaces.

**RESULTS**

Eleven patients fulfilling the inclusion criteria were enrolled into the study. There were two male and nine female patients (median age 37 years (range 19–60)). All patients had a normal clinical examination and presented with persistently abnormal liver function tests (mainly raised gamma glutamyl transferase), which led to liver biopsy.

Associated conditions are presented in table 1. Among 11 patients, associated conditions were prothrombotic disorders (n = 5) and oral contraceptive use (n = 3). Prothrombotic disorders were polycthemia vera (n = 1) and anticardiolipin antibodies combined with lupus anticoagulant (n = 4). No genetic thrombophilia factor was found. All four patients had lupus anticoagulant and three had antinuclear factors and high serum levels of anticardiolipin antibodies at repeated testing. None had clinical or laboratory evidence of connective tissue disease. Oral contraceptive use was the sole associated condition in one patient. No associated condition was found in four patients.

**DISCUSSION**

This study indicates that idiopathic pure HSD is associated with immunological features of antiphospholipid syndrome. In contrast with other primary vascular disorders of the liver, HSD was associated with only one case of occult primary myeloproliferative disorder and no cases of heritable thrombophilia. Antiphospholipid syndrome has not yet been reported to cause sinusoidal dilatation. Thus the fact that antiphospholipid antibodies accounted for four out of five

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Specific features</th>
<th>Medications</th>
<th>ALT (×UN)</th>
<th>GGT (×UN)</th>
<th>AP (×UN)</th>
<th>LA</th>
<th>Anticardiolipin antibodies</th>
<th>ANA</th>
<th>Sinusoidal dilatation</th>
<th>Activated perisinusoidal cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (F/31)</td>
<td>2 previous early abortions. Thrombocytopenia. Familial thrombophilia.</td>
<td>None</td>
<td>3</td>
<td>8</td>
<td>3.5</td>
<td>+</td>
<td>IgG 52 and 45 GPL</td>
<td>1/500</td>
<td>Moderate</td>
<td>Absent</td>
</tr>
<tr>
<td>2 (F/29)</td>
<td>Unremarkable</td>
<td>None</td>
<td>1.5</td>
<td>4</td>
<td>3.5</td>
<td>+</td>
<td>IgG 40 and 45 GPL</td>
<td>IgM &lt;10 MPL</td>
<td>1/500</td>
<td>Marked</td>
</tr>
<tr>
<td>3 (M/39)</td>
<td>Unremarkable</td>
<td>None</td>
<td>3.2</td>
<td>2.5</td>
<td>4.1</td>
<td>+</td>
<td>IgG 40 and 45 GPL</td>
<td>IgM &lt;10 MPL</td>
<td>1/250</td>
<td>Moderate</td>
</tr>
<tr>
<td>4 (F/52)</td>
<td>Unremarkable</td>
<td>None</td>
<td>3.3</td>
<td>3.8</td>
<td>5</td>
<td>+</td>
<td>IgG &lt;10 GPL</td>
<td>IgM 15 and 22 MPL</td>
<td>Neg</td>
<td>Marked</td>
</tr>
<tr>
<td>5 (F/36)</td>
<td>Occult myeloproliferative disorder</td>
<td>Oestro-progestatives</td>
<td>2</td>
<td>5</td>
<td>2.4</td>
<td>Neg</td>
<td>IgG 52 and 45 GPL</td>
<td>IgM 10 (titre)</td>
<td>Neg</td>
<td>Moderate</td>
</tr>
<tr>
<td>6 (F/25)</td>
<td>Unremarkable</td>
<td>Oestro-progestatives</td>
<td>2</td>
<td>6.3</td>
<td>3.3</td>
<td>Neg</td>
<td>IgG 52 and 45 GPL</td>
<td>IgM 10 MPL</td>
<td>Neg</td>
<td>Marked</td>
</tr>
<tr>
<td>7 (M/60)</td>
<td>Unremarkable</td>
<td>None</td>
<td>2.1</td>
<td>2</td>
<td>3</td>
<td>Neg</td>
<td>Neg</td>
<td>LA</td>
<td>Marked</td>
<td>Absent</td>
</tr>
<tr>
<td>8 (F/20)</td>
<td>Unremarkable</td>
<td>None</td>
<td>3</td>
<td>7</td>
<td>3.1</td>
<td>Neg</td>
<td>IgM 10 (titre)</td>
<td>IgM 10 GPL</td>
<td>Neg</td>
<td>Moderate</td>
</tr>
<tr>
<td>9 (F/47)</td>
<td>Unremarkable</td>
<td>None</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>Neg</td>
<td>Neg</td>
<td>LA</td>
<td>Moderate</td>
<td>Absent</td>
</tr>
<tr>
<td>10 (F/32)</td>
<td>Unremarkable</td>
<td>None</td>
<td>3.1</td>
<td>7.3</td>
<td>2</td>
<td>Neg</td>
<td>IgM 10 (titre)</td>
<td>IgM 10 GPL</td>
<td>Neg</td>
<td>Moderate</td>
</tr>
<tr>
<td>11 (F/31)</td>
<td>Unremarkable</td>
<td>Oestro-progestatives</td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>Neg</td>
<td>LA</td>
<td>Marked</td>
<td>Absent</td>
<td></td>
</tr>
</tbody>
</table>

F, female; M, male; ALT, serum alanine aminotransferase; GGT, serum gamma glutamyl transpeptidase; AP, serum alkaline phosphatase; UNL, times the upper limit of normal values; LA, lupus anticoagulant; ANA, antinuclear antibodies; Neg, not detectable.

*Positive when >10 GPL units for IgG and 10 MPL units for IgM in commercial ELISA (Cheshire Diagnostics, Chester, UK). Tested at least twice, six weeks apart.

†Immunofluorescence on Hep2 cells.
identified prothrombotic disorders is an important finding of this study. The prevalence of antiphospholipid antibodies in this cohort was 36% (four of 11 patients) compared with a reported maximum of 5% among young apparently healthy control subjects. At repeat testing, all four patients had the lupus anticoagulant (including three with high serum levels of antinuclear factors and anticardiolipin antibodies), a feature that is associated with thrombophilia. However, none of our patients had evidence of present or past thrombosis. None strictly fulfilled the criteria for antiphospholipid syndrome. Except for autoantibodies, there was no evidence of a connective tissue disease. Oral contraceptive use, another potential cause of sinusoidal dilatation, was present in only three patients in this cohort, none of whom had antiphospholipid antibodies. This fact argues against a prominent role of oral contraceptives. Thus persistently abnormal liver biochemistry was the only clue to HSD and, eventually, to the presence of the immunological anomalies. Therefore, finding idiopathic pure HSD in a liver biopsy specimen should prompt the search for antiphospholipid antibodies. Furthermore, in patients with antiphospholipid antibodies and abnormal liver function tests, sinusoidal dilatation should be considered.

Contrasting with the prothrombotic disorders documented in five patients, HSD could not be readily explained by microvascular thromboses. As reviewed elsewhere, perisinusoidal cells can modulate sinusoidal calibre; they are activated by thrombin and, when activated, contribute to hepatic fibrogenesis. Indeed, perisinusoidal fibrosis and sinusoidal dilatation are frequently found in non-cirrhotic intrahepatic portal hypertension associated with prothrombotic disorders. However, in this cohort, activated perisinusoidal cells were found only around markedly dilated sinusoids, suggesting a consequence rather than a cause of HSD. Thus the mechanism leading to HSD, whether related or not to antiphospholipid antibodies, remains elusive. Although unproven, sinusoidal outflow obstruction is a likely mechanism, at least in cases where a prothrombotic disorder is found. Alternatively, it can be hypothesised that direct injury to hepatic endothelial cell by antiphospholipid antibodies may contribute to the sinusoidal lining disruption leading to the formation of HSD. Along this line, recent studies demonstrated that vascular endothelial cell injury plays a major role in the pathogenesis of antiphospholipid syndrome.

Whether the entity combining idiopathic pure HSD and antiphospholipid antibodies can be regarded as a variant of antiphospholipid syndrome is relevant for issues of outcome and therapy. Over a 2–5 year follow up, all four patients with antiphospholipid antibodies have remained asymptomatic with stable liver biochemistry. The benefit of anticoagulation in patient No 1 (with a history of two abortions, low platelet counts, and a familial history of thrombophilia) remains unproved. However, antiphospholipid syndrome can cause severe vascular disorders of the liver, including non-cirrhotic intrahepatic portal hypertension, and portal vein or hepatic vein thrombosis. Whether idiopathic pure HSD associated with antiphospholipid antibodies heralds the development of these severe complications requires further clarification. At present, anticoagulation cannot be recommended as there was no evidence of vascular obstruction or thrombosis, and short term outcome was excellent.

Authors' affiliations
D Saadoun, V Mallet, B Condat, D Valla, Service d’Hépatologie and INSERM U 481, Hôpital Beaujon (Assistance Publique-Hôpitaux de Paris, Université Paris 7), Clichy, France
D Cazals-Hatem, Service d’Anatomie et de Cytologie Pathologiques, Hôpital Beaujon (Assistance Publique-Hôpitaux de Paris, Université Paris 7), Clichy, France
M-H Denninger, L Boudaoud, B-N Pham, Service d’Hématologie et d’Immunologie, Hôpital Beaujon (Assistance Publique-Hôpitaux de Paris, Université Paris 7), Clichy, France
J Brière, Service d’Hématologie Clinique, Hôpital Beaujon (Assistance Publique-Hôpitaux de Paris, Université Paris 7), Clichy, France

Figure 1 Marked sinusoidal dilatation, prominent in the mediolobular zone of the lobule (zone 2) (A, ×100) with detection of α-smooth muscle actin positive perisinusoidal cells (B, arrows, ×250). Moderate sinusoidal dilatation in zones 2 and 3 (C, ×100), with no α-smooth muscle actin positive cells detected (D, ×250).
REFERENCES

Association of idiopathic hepatic sinusoidal dilatation with the immunological features of the antiphospholipid syndrome

D Saadoun, D Cazals-Hatem, M-H Denninger, L Boudaoud, B-N Pham, V Mallet, B Condat, J Brière and D Valla

Gut 2004 53: 1516-1519
doi: 10.1136/gut.2003.037135

Updated information and services can be found at:
http://gut.bmj.com/content/53/10/1516

These include:

References

This article cites 27 articles, 3 of which you can access for free at:
http://gut.bmj.com/content/53/10/1516#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/